hepatocellular carcinoma xenograft model, combination therapy of sunitinib and PF-562271 targets angiogenesis and tumor aggressiveness, and produces more significant anti-tumor effect than single agent by blocking tumor growth and impacting the ability of the tumor to recover upon withdrawal of the ...
I'm using @Risk software fromPalisadeto conduct the stress test. The result: - 80% chance I can live only by the withdrawals without any problem. - 90% chance the plan will work for 27 to 43 years, although I need to take withdrawal cut (Assumption #9) between 2 to 9 years. I'm...